http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013179302-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7749e7b6dabfd36d65282b80c64e272
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-208
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-204
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-191
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2033
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
filingDate 2013-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0abe1634c0c9dc13534b68e73d31b2ca
publicationDate 2013-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2013179302-A1
titleOfInvention Oral anti-inflammatory formulation comprising potentised cytokine
abstract The present disclosure provides an anti-inflammatory formulation comprising a homogenized mixture of at least one potentised cytokines selected from the group consisting of IL la (interleukin 1-alpha), IL lb (interleukin 1-beta), IL 2, IL 4, IL 5, IL 6, TNF-a (Tumor Necrosis Factor-alpha), INF-γ, IL 12, IL 13, IL 17, IL 20 and IL 23.
priorityDate 2012-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012026771-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010134086-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0307097-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012064122-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012058205-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4112
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395836
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5839
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395835
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128954713
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID222786
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394333
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID126941
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396789
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128590101

Total number of triples: 45.